Smoking Tobacco

8

Review clinical trials related to Smoking Tobacco. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

The Efficacy of Conventional Screening Versus mHealth Screening in Early Detection of Oral Potentially Malignant Disorders and Oral Cancer Amongst the Rural Population of Varanasi: A Prospective and Blinded Study

Mobile health (mHealth) will be used for early detection of oral cancer and pre-cancer lesions, and to improve awareness of oral cancer among the population and knowledge of oral cancer diagnosis among frontline health providers. This program is inclusive of long term surveillance to downstage oral cancer in India

Participants needed: 5,122
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Memorial Sloan Kettering Cancer CenterUpdated: May 22, 2026Locations: 1
Eligibility criteria

All individuals aged above 18 years positive for habits (smoking and smokeless t... [+2]

Individuals already diagnosed with oral cancer and undergoing treatment for oral... [+1]

Status: Recruiting

TUBSIS 2.0 - Tobacco Use Behavioral Support and Intervention System

Background: Tobacco smoking and vaping remains public health concern, with many adults continuing to experience difficulties accessing appropriate support for smoking cessation in Switzerland and Türkiye. Structural barriers, including stigma related to attempting to quit, limited financial and time resources, low awareness of the health risks associated with tobacco smoking- and vaping-reduce engagement with traditional services. TUBSIS 2.0 aims to address these access inequities by providing a fully remote, anonymous and free internet-based program tailored to diverse adult populations in both countries. Objectives: The "TUBSIS 2.0: An Adaptation Study of Tobacco Addiction Support Programme - TUBSIS for Tobacco Users in Switzerland and Türkiye" project aims to support readiness to reduce or quit tobacco smoking/vaping, improve well-being and self-compassion and strengthen health-related behaviors. The intervention targets German-, English-, and Turkish-speaking adults and includes mindfulness-based strategies for quitting or reducing tobacco smoking and vaping. Motivation to cease tobacco smoking/vaping varies considerably across the lifespan. Younger individuals may perceive smoking/vaping cessation as unnecessary, often due to limited awareness of long-term health risks or a sense of invulnerability. In later adulthood, although addiction tends to be more deeply established, many individuals hesitate to attempt cessation because of concerns about the psychological and behavioral challenges associated with the process. It is therefore essential to provide individuals with support that helps them understand the cessation process, prepare for the challenges that can be expected and identify strategies that align with their psychological needs. Such strategies may include stress management and self-compassion practices that can be utilized before, during and after cessation attempts. TUBSIS 2.0 offers structured and accessible guidance to support this preparation by providing a clear, evidence-based pathway for individuals at different stages of readiness to change. Methods: TUBSIS 2.0 is a web-based, individual and asynchronous program consisting of eight modules delivered over four weeks. A total of 406 participants will be recruited and randomly assigned to either the intervention or control group. Data are collected anonymously at four measurement points (baseline, mid-term, post-term and 8-week follow-up) from participants. The program focuses on supporting participants' reducing or quitting tobacco smoking or vaping; to increase their readiness for smoking/vaping cessation, mental well-being, self-compassion and stress management with mindfulness strategies. Within the Health Action Process Approach (HAPA), the process of behaviour change is conceptualised as a dynamic, non-linear process that progresses through motivational and volitional phases. TUBSIS 2.0 has been adapted to reflect this structure by integrating phase-specific components. These components include modules that enhance risk awareness and outcome expectancies, planning and self-regulation tools to support action initiation and mindfulness-based strategies that are embedded throughout all phases to strengthen self-efficacy and coping. By addressing these shifting needs across the change process, the programme provides a responsive and theory-driven pathway for reducing/quitting tobacco smoking or vaping. Relevance: TUBSIS 2.0 is highly relevant to public health priorities, as it provides a cost-effective, scalable and environmentally sustainable intervention that eliminates barriers commonly associated with traditional cessation services. By requiring no travel, printed materials or in-person appointments, the programme offers equitable access to adults across all age groups, genders and diverse migrant communities in Switzerland and Türkiye. Its multilingual and culturally adapted structure addresses significant service gaps for populations that are underserved or hesitant to seek conventional support. By reducing tobacco smoking- or vaping-related harm and facilitating early behavioural change, TUBSIS 2.0 has the potential to decrease long-term healthcare costs while expanding access to evidence-based digital prevention tools.

Participants needed: 406
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: University of ZurichUpdated: May 5, 2026Locations: 1
Eligibility criteria

Age: 18 years or older [+5]

Individuals who do not meet the inclusion criteria are excluded.

Status: Recruiting

Leveraging Community Pharmacists to Optimize Smoking Cessation Services for Rural Smokers in Appalachia

The goal of this clinical trial is to evaluate the effectiveness and implementation of a pharmacist-delivered MTM (medication therapy management) approach, called QuitAid, to quitting cigarette smoking in rural Appalachia. The main questions it aims to answer are: * Is QuitAid, alone or combined with other quitting tobacco treatments, effective? * What makes QuitAid easy or hard to carry out? Is it cost effective? Is it easy to maintain? Treatment: All participants will be given at least 4 weeks of the nicotine patch. Some participants will be randomized (like the flip of a coin) to receive additional treatments (listed below). These groups will be compared to each other to see which combination works best to help them quit smoking. * Smokefree TXT - a texting program that helps people quit smoking * Tobacco quitline - 4 phone sessions to help people quit smoking * 8 weeks of NRT (nicotine replacement therapy in the form of nicotine patches or nicotine patches and lozenge) medication instead of 4 weeks * QuitAid - An MTM program given by the patient's pharmacist. This is a quitting smoking coaching program * Nicotine patch AND nicotine lozenge instead of just nicotine patches

Participants needed: 768
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: University of VirginiaUpdated: Apr 20, 2026Locations: 1
Eligibility criteria

must be 18 years of age and older [+6]

are pregnant women (self-reported), breastfeeding, planning to become pregnant d... [+1]

Status: Recruiting

ACT Lung Health Intervention: Phase Two

This study aims to test a counseling and educational program designed to improve lung health through smoking cessation for Chinese and Korean American smokers at high risk for lung cancer.

Participants needed: 50
Trial details
Age: 18-100Biological sex: AllType: InterventionalSponsor: Dana-Farber Cancer InstituteUpdated: Mar 13, 2026Locations: 2
Eligibility criteria

Self-identify as either Chinese or Korean [+4]

Hospitalization due to a serious mental illness (e.g., psychotic disorders) duri... [+5]

Status: Recruiting

A Study Evaluating the Use of an Indoor Air Quality Monitor to Promote a Smoke-free Home

The purpose of this study is to evaluate how using an indoor air quality monitor can promote a smoke-free home for cancer patients who are enrolled in MSK's Tobacco Treatment Program.

Participants needed: 10
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Memorial Sloan Kettering Cancer CenterUpdated: Oct 22, 2025Locations: 8
Eligibility criteria

Adult (aged >18 years) MSK patients as per the EHR [+5]

Patient reports that no smoking is allowed, by them or anyone else, in the home...

Status: Recruiting

Respiratory Function and Oxygenation in Smokers and Non-smokers

This study aimed to compare respiratory function, exercise capacity, and intercostal muscle oxygenation in healthy smokers and non-smokers.

Participants needed: 42
Trial details
Age: 18-65Biological sex: AllType: ObservationalSponsor: Kirsehir Ahi Evran UniversitesiUpdated: Jun 19, 2025Locations: 1
Eligibility criteria

According to the World Health Organization and ICD smoking addiction criteria, c... [+2]

Having any cardiopulmonary disease [+8]

Status: Recruiting

V+PSF-M for Tobacco Cessation in HIV Care in India

The goal of this research study is to test an intervention to help quit tobacco use in participants with Human Immunodeficiency Virus (HIV). The study interventions used in this research study are: * Positively Smoke Free - Mobile (PSF-M) (mobile behavioral program) * Varenicline (or Chantix, apovarenicline, Champix or Nocrav)

Participants needed: 400
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: University of Colorado, DenverUpdated: Jun 15, 2025Locations: 2
Eligibility criteria

Adults (≥18 years) [+6]

Pregnant or planning to become pregnant in the next 6 months [+10]

Status: Recruiting

Cue Effects in Human Addiction: Pavlovian to Instrumental Transfer

Individuals with substance use disorders (SUD) have to cope with drug-related cues and contexts, which can affect instrumental drug seeking as shown with Pavlovian to instrumental transfer (PIT) paradigms in animals and humans. The investigators aimed to investigate the impact of acute and chronic stress on Pavlovian-to-instrumental transfer (PIT), how PIT it is associated with cognitive control abilities and whether such effects predict losing vs. regaining control in subjects with AUD. Moreover, the investigators aimed to develop a novel full transfer task that assesses both, general and specific PIT to investigate whether specific PIT differs between alcohol use disorder (AUD) and control subjects.

Participants needed: 300
Trial details
Age: 16-65Biological sex: AllType: ObservationalSponsor: Charite University, Berlin, GermanyUpdated: Aug 21, 2024Locations: 2
Eligibility criteria

males and females between 16-65 years of age [+7]

Lifetime diagnosis according to DMS-5 for: Bipolar disorder, schizophrenia, schi... [+11]